Yang Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yang Zhao has a total of 117 co-authors. Here are the top co-authors by number of shared publications:
- K. Christopher Garcia
Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA
5 shared publications - Masato Ogishi
St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY, USA
4 shared publications - Grayson E. Rodriguez
Immunology Program, Stanford University, Stanford, CA, USA
3 shared publications - Anusha Kalbasi
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA
2 shared publications Deepa Waghray
Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA
2 shared publicationsHua Jiang
Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, USA
2 shared publications
Latest Publications
- Open Access
- 14 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 392 (6799) , eadx9954
Rewiring STAT signaling from the cell surface with Trikine immunotherapeutics
Cytokines dimerize two receptor chains to activate Janus kinases and signal transducer and activator of transcription (STAT) transcription factors that regulate immune cells, but they have therapeutic liabilities. We engineered “Trikines” to compel cis formation of three-chain cytokine receptor complexes at the cell surface that induce bespoke STAT transcriptional signaling programs. Trikines coactivated phosphorylation of STAT5 (pSTAT5) and pSTAT3 signatures distinct from natural cytokines by assembling trimeric combinations of interleukin-2 (IL-2), IL-10, and IL-21 receptors. In preclinical models, an IL-2–based Trikine restrained terminal differentiation of T cells, promoted stemness, and enhanced durability of tumor control without observable toxicity. An IL-10–based Trikine induced immune infiltration into poorly immunogenic tumors, showing efficacy in preclinical models of small cell lung cancer and pancreatic cancer. Trikines obviate the need for cell engineering to customize STAT signatures and may hold potential for immunotherapy.
- 14 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 392 (6799) , eadx9954
Open AccessRewiring STAT signaling from the cell surface with Trikine immunotherapeutics
Cytokines dimerize two receptor chains to activate Janus kinases and signal transducer and activator of transcription (STAT) transcription factors that regulate immune cells, but they have therapeutic liabilities. We engineered “Trikines” to compel cis formation of three-chain cytokine receptor complexes at the cell surface that induce bespoke STAT transcriptional signaling programs. Trikines coactivated phosphorylation of STAT5 (pSTAT5) and pSTAT3 signatures distinct from natural cytokines by assembling trimeric combinations of interleukin-2 (IL-2), IL-10, and IL-21 receptors. In preclinical models, an IL-2–based Trikine restrained terminal differentiation of T cells, promoted stemness, and enhanced durability of tumor control without observable toxicity. An IL-10–based Trikine induced immune infiltration into poorly immunogenic tumors, showing efficacy in preclinical models of small cell lung cancer and pancreatic cancer. Trikines obviate the need for cell engineering to customize STAT signatures and may hold potential for immunotherapy.
- Open Access
- 11 March 2026
- Published by Springer Nature in Nature
- Vol. 653 (8115) , 888-899
Facile induction of immune tolerance by an interleukin-2–TGFβ surrogate agonist
CD4 + regulatory T cells (T reg cells) are essential for immune tolerance 1 . Peripherally induced T reg cells (pT reg cells) complement thymic T reg cells by broadening T reg cell reactivity in response to a changing antigenic landscape 2 . Although both TGFβ and IL-2 synergistically promote functional pT reg cell development in vitro 3–6 , their combined roles in inducing pT reg cell generation in vivo have not been exploited for tolerizing immunotherapy. Here we designed an IL-2–TGFβ ‘surrogate’ co-agonist by creating a single-chain fusion protein between IL-2 and a low-affinity TGFβ mimic agonist derived from a helminth parasite 7 . This IL-2–TGFβ surrogate functions as an AND-gated co-agonist and enabled simultaneous cis -activation of IL-2–STAT5 and TGFβ–SMAD2/3 signalling specifically in T cells that express IL-2 receptors. The IL-2–TGFβ surrogate agonist robustly induced antigen-specific, functional and stable pT reg cells in vivo within peripheral lymphoid organs in mice immunized with ovalbumin (OVA) and myelin oligodendrocyte glycoprotein (MOG) 35–55 . The induced pT reg cells display an effector-like, actively expanding state with high RORγt expression, enabling efficient migration and suppression of intestinal inflammation. Treatment with this agonist effectively quelled immune activation in mouse models of allergen-induced allergic inflammation and self-antigen-driven autoimmune neuroinflammation, suggesting a strategy for the induction of antigen-specific pT reg cells in vivo to establish immune tolerance in inflammatory, allergic and autoimmune diseases.
- 11 March 2026
- Published by Springer Nature in Nature
- Vol. 653 (8115) , 888-899
Open AccessFacile induction of immune tolerance by an interleukin-2–TGFβ surrogate agonist
CD4 + regulatory T cells (T reg cells) are essential for immune tolerance 1 . Peripherally induced T reg cells (pT reg cells) complement thymic T reg cells by broadening T reg cell reactivity in response to a changing antigenic landscape 2 . Although both TGFβ and IL-2 synergistically promote functional pT reg cell development in vitro 3–6 , their combined roles in inducing pT reg cell generation in vivo have not been exploited for tolerizing immunotherapy. Here we designed an IL-2–TGFβ ‘surrogate’ co-agonist by creating a single-chain fusion protein between IL-2 and a low-affinity TGFβ mimic agonist derived from a helminth parasite 7 . This IL-2–TGFβ surrogate functions as an AND-gated co-agonist and enabled simultaneous cis -activation of IL-2–STAT5 and TGFβ–SMAD2/3 signalling specifically in T cells that express IL-2 receptors. The IL-2–TGFβ surrogate agonist robustly induced antigen-specific, functional and stable pT reg cells in vivo within peripheral lymphoid organs in mice immunized with ovalbumin (OVA) and myelin oligodendrocyte glycoprotein (MOG) 35–55 . The induced pT reg cells display an effector-like, actively expanding state with high RORγt expression, enabling efficient migration and suppression of intestinal inflammation. Treatment with this agonist effectively quelled immune activation in mouse models of allergen-induced allergic inflammation and self-antigen-driven autoimmune neuroinflammation, suggesting a strategy for the induction of antigen-specific pT reg cells in vivo to establish immune tolerance in inflammatory, allergic and autoimmune diseases.
- Open Access
- 24 September 2025
- Published by Springer Nature in Nature
- Vol. 647 (8089) , 528-535
Design of facilitated dissociation enables timing of cytokine signalling
Protein design has focused on the design of ground states, ensuring that they are sufficiently low energy to be highly populated 1 . Designing the kinetics and dynamics of a system requires, in addition, the design of excited states that are traversed in transitions from one low-lying state to another 2,3 . This is a challenging task because such states must be sufficiently strained to be poorly populated, but not so strained that they are not populated at all, and because protein design methods have focused on generating near-ideal structures 4–7 . Here we describe a general approach for designing systems that use an induced-fit power stroke 8 to generate a structurally frustrated 9 and strained excited state, allosterically driving protein complex dissociation. X-ray crystallography, double electron–electron resonance spectroscopy and kinetic binding measurements show that incorporating excited states enables the design of effector-induced increases in dissociation rates as high as 5,700-fold. We highlight the power of this approach by designing rapid biosensors, kinetically controlled circuits and cytokine mimics that can be dissociated from their receptors within seconds, enabling dissection of the temporal dynamics of interleukin-2 signalling.
- 24 September 2025
- Published by Springer Nature in Nature
- Vol. 647 (8089) , 528-535
Open AccessDesign of facilitated dissociation enables timing of cytokine signalling
Protein design has focused on the design of ground states, ensuring that they are sufficiently low energy to be highly populated 1 . Designing the kinetics and dynamics of a system requires, in addition, the design of excited states that are traversed in transitions from one low-lying state to another 2,3 . This is a challenging task because such states must be sufficiently strained to be poorly populated, but not so strained that they are not populated at all, and because protein design methods have focused on generating near-ideal structures 4–7 . Here we describe a general approach for designing systems that use an induced-fit power stroke 8 to generate a structurally frustrated 9 and strained excited state, allosterically driving protein complex dissociation. X-ray crystallography, double electron–electron resonance spectroscopy and kinetic binding measurements show that incorporating excited states enables the design of effector-induced increases in dissociation rates as high as 5,700-fold. We highlight the power of this approach by designing rapid biosensors, kinetically controlled circuits and cytokine mimics that can be dissociated from their receptors within seconds, enabling dissection of the temporal dynamics of interleukin-2 signalling.
- Open Access
- 13 August 2025
- Published by Springer Nature in Nature
- Vol. 645 (8082) , 1039-1050
Expanding the cytokine receptor alphabet reprograms T cells into diverse states
T cells respond to cytokines through receptor dimers that have been selected over the course of evolution to activate canonical JAK-STAT signalling and gene expression programs1. However, the potential combinatorial diversity of JAK-STAT receptor pairings can be expanded by exploring the untapped biology of alternative non-natural pairings. Here we exploited the common γ chain (γc) receptor as a shared signalling hub on T cells and enforced the expression of both natural and non-natural heterodimeric JAK-STAT receptor pairings using an orthogonal cytokine receptor platform2-4 to expand the γc signalling code. We tested receptors from γc cytokines as well as interferon, IL-10 and homodimeric receptor families that do not normally pair with γc or are not naturally expressed on T cells. These receptors simulated their natural counterparts but also induced contextually unique transcriptional programs. This led to distinct T cell fates in tumours, including myeloid-like T cells with phagocytic capacity driven by orthogonal GSCFR (oGCSFR), and type 2 cytotoxic T (TC2) and helper T (TH2) cell differentiation driven by orthogonal IL-4R (o4R). T cells with orthogonal IL-22R (o22R) and oGCSFR, neither of which are natively expressed on T cells, exhibited stem-like and exhaustion-resistant transcriptional and chromatin landscapes, enhancing anti-tumour properties. Non-native receptor pairings and their resultant JAK-STAT signals open a path to diversifying T cell states beyond those induced by natural cytokines.
- 13 August 2025
- Published by Springer Nature in Nature
- Vol. 645 (8082) , 1039-1050
Open AccessExpanding the cytokine receptor alphabet reprograms T cells into diverse states
T cells respond to cytokines through receptor dimers that have been selected over the course of evolution to activate canonical JAK-STAT signalling and gene expression programs1. However, the potential combinatorial diversity of JAK-STAT receptor pairings can be expanded by exploring the untapped biology of alternative non-natural pairings. Here we exploited the common γ chain (γc) receptor as a shared signalling hub on T cells and enforced the expression of both natural and non-natural heterodimeric JAK-STAT receptor pairings using an orthogonal cytokine receptor platform2-4 to expand the γc signalling code. We tested receptors from γc cytokines as well as interferon, IL-10 and homodimeric receptor families that do not normally pair with γc or are not naturally expressed on T cells. These receptors simulated their natural counterparts but also induced contextually unique transcriptional programs. This led to distinct T cell fates in tumours, including myeloid-like T cells with phagocytic capacity driven by orthogonal GSCFR (oGCSFR), and type 2 cytotoxic T (TC2) and helper T (TH2) cell differentiation driven by orthogonal IL-4R (o4R). T cells with orthogonal IL-22R (o22R) and oGCSFR, neither of which are natively expressed on T cells, exhibited stem-like and exhaustion-resistant transcriptional and chromatin landscapes, enhancing anti-tumour properties. Non-native receptor pairings and their resultant JAK-STAT signals open a path to diversifying T cell states beyond those induced by natural cytokines.
- 24 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 389 (6758) , 375-379
De novo design and structure of a peptide–centric TCR mimic binding module
T cell receptor (TCR) mimics offer a promising platform for tumor-specific targeting of peptide–major histocompatibility complex (pMHC) in cancer immunotherapy. In this study, we designed a de novo α-helical TCR mimic (TCRm) specific for the NY-ESO-1 peptide presented by human leukocyte antigen (HLA)–A*02, achieving high on-target specificity with nanomolar affinity (dissociation constant K d = 9.5 nM). The structure of the TCRm-pMHC complex at 2.05-Å resolution revealed a rigid TCR-like docking mode with an unusual degree of focus on the up-facing NY-ESO-1 side chains, suggesting the potential for reduced off-target reactivity. Indeed, a structure-informed in silico screen of 14,363 HLA-A*02 peptides correctly predicted two off-target peptides, yet our TCRm maintained peptide selectivity and cytotoxicity as a T cell engager. These results represent a path for precision targeting of tumor antigens with peptide-focused α-helical TCR mimics.
- 24 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 389 (6758) , 375-379
De novo design and structure of a peptide–centric TCR mimic binding module
T cell receptor (TCR) mimics offer a promising platform for tumor-specific targeting of peptide–major histocompatibility complex (pMHC) in cancer immunotherapy. In this study, we designed a de novo α-helical TCR mimic (TCRm) specific for the NY-ESO-1 peptide presented by human leukocyte antigen (HLA)–A*02, achieving high on-target specificity with nanomolar affinity (dissociation constant K d = 9.5 nM). The structure of the TCRm-pMHC complex at 2.05-Å resolution revealed a rigid TCR-like docking mode with an unusual degree of focus on the up-facing NY-ESO-1 side chains, suggesting the potential for reduced off-target reactivity. Indeed, a structure-informed in silico screen of 14,363 HLA-A*02 peptides correctly predicted two off-target peptides, yet our TCRm maintained peptide selectivity and cytotoxicity as a T cell engager. These results represent a path for precision targeting of tumor antigens with peptide-focused α-helical TCR mimics.
- Top Cited PapersOpen Access
- 25 September 2024
- Published by Springer Nature in Nature
- Vol. 634 (8034) , 712-720
The type 2 cytokine Fc–IL-4 revitalizes exhausted CD8+ T cells against cancer
Current cancer immunotherapy predominately focuses on eliciting type 1 immune responses fighting cancer; however, long-term complete remission remains uncommon1,2. A pivotal question arises as to whether type 2 immunity can be orchestrated alongside type 1-centric immunotherapy to achieve enduring response against cancer3,4. Here we show that an interleukin-4 fusion protein (Fc–IL-4), a typical type 2 cytokine, directly acts on CD8+ T cells and enriches functional terminally exhausted CD8+ T (CD8+ TTE) cells in the tumour. Consequently, Fc–IL-4 enhances antitumour efficacy of type 1 immunity-centric adoptive T cell transfer or immune checkpoint blockade therapies and induces durable remission across several syngeneic and xenograft tumour models. Mechanistically, we discovered that Fc–IL-4 signals through both signal transducer and activator of transcription 6 (STAT6) and mammalian target of rapamycin (mTOR) pathways, augmenting the glycolytic metabolism and the nicotinamide adenine dinucleotide (NAD) concentration of CD8+ TTE cells in a lactate dehydrogenase A-dependent manner. The metabolic modulation mediated by Fc–IL-4 is indispensable for reinvigorating intratumoural CD8+ TTE cells. These findings underscore Fc–IL-4 as a potent type 2 cytokine-based immunotherapy that synergizes effectively with type 1 immunity to elicit long-lasting responses against cancer. Our study not only sheds light on the synergy between these two types of immune responses, but also unveils an innovative strategy for advancing next-generation cancer immunotherapy by integrating type 2 immune factors.
- 25 September 2024
- Published by Springer Nature in Nature
- Vol. 634 (8034) , 712-720
Top Cited PapersOpen AccessThe type 2 cytokine Fc–IL-4 revitalizes exhausted CD8+ T cells against cancer
Current cancer immunotherapy predominately focuses on eliciting type 1 immune responses fighting cancer; however, long-term complete remission remains uncommon1,2. A pivotal question arises as to whether type 2 immunity can be orchestrated alongside type 1-centric immunotherapy to achieve enduring response against cancer3,4. Here we show that an interleukin-4 fusion protein (Fc–IL-4), a typical type 2 cytokine, directly acts on CD8+ T cells and enriches functional terminally exhausted CD8+ T (CD8+ TTE) cells in the tumour. Consequently, Fc–IL-4 enhances antitumour efficacy of type 1 immunity-centric adoptive T cell transfer or immune checkpoint blockade therapies and induces durable remission across several syngeneic and xenograft tumour models. Mechanistically, we discovered that Fc–IL-4 signals through both signal transducer and activator of transcription 6 (STAT6) and mammalian target of rapamycin (mTOR) pathways, augmenting the glycolytic metabolism and the nicotinamide adenine dinucleotide (NAD) concentration of CD8+ TTE cells in a lactate dehydrogenase A-dependent manner. The metabolic modulation mediated by Fc–IL-4 is indispensable for reinvigorating intratumoural CD8+ TTE cells. These findings underscore Fc–IL-4 as a potent type 2 cytokine-based immunotherapy that synergizes effectively with type 1 immunity to elicit long-lasting responses against cancer. Our study not only sheds light on the synergy between these two types of immune responses, but also unveils an innovative strategy for advancing next-generation cancer immunotherapy by integrating type 2 immune factors.
- Top Cited Papers
- 2 January 2024
- Published by Springer Nature in Nature Biotechnology
- Vol. 42 (11) , 1693-1704
IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases
The success of chimeric antigen receptor (CAR) T cell therapy in treating several hematopoietic malignancies has been difficult to replicate in solid tumors, in part because of T cell exhaustion and eventually dysfunction. To counter T cell dysfunction in the tumor microenvironment, we metabolically armored CAR T cells by engineering them to secrete interleukin-10 (IL-10). We show that IL-10 CAR T cells preserve intact mitochondrial structure and function in the tumor microenvironment and increase oxidative phosphorylation in a mitochondrial pyruvate carrier-dependent manner. IL-10 secretion promoted proliferation and effector function of CAR T cells, leading to complete regression of established solid tumors and metastatic cancers across several cancer types in syngeneic and xenograft mouse models, including colon cancer, breast cancer, melanoma and pancreatic cancer. IL-10 CAR T cells also induced stem cell-like memory responses in lymphoid organs that imparted durable protection against tumor rechallenge. Our results establish a generalizable approach to counter CAR T cell dysfunction through metabolic armoring, leading to solid tumor eradication and long-lasting immune protection.
- 2 January 2024
- Published by Springer Nature in Nature Biotechnology
- Vol. 42 (11) , 1693-1704
Top Cited PapersIL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases
The success of chimeric antigen receptor (CAR) T cell therapy in treating several hematopoietic malignancies has been difficult to replicate in solid tumors, in part because of T cell exhaustion and eventually dysfunction. To counter T cell dysfunction in the tumor microenvironment, we metabolically armored CAR T cells by engineering them to secrete interleukin-10 (IL-10). We show that IL-10 CAR T cells preserve intact mitochondrial structure and function in the tumor microenvironment and increase oxidative phosphorylation in a mitochondrial pyruvate carrier-dependent manner. IL-10 secretion promoted proliferation and effector function of CAR T cells, leading to complete regression of established solid tumors and metastatic cancers across several cancer types in syngeneic and xenograft mouse models, including colon cancer, breast cancer, melanoma and pancreatic cancer. IL-10 CAR T cells also induced stem cell-like memory responses in lymphoid organs that imparted durable protection against tumor rechallenge. Our results establish a generalizable approach to counter CAR T cell dysfunction through metabolic armoring, leading to solid tumor eradication and long-lasting immune protection.
- 30 March 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (14)
ICAM-1 orchestrates the abscopal effect of tumor radiotherapy
Compelling evidence indicates that radiotherapy (RT) has a systemic inhibitory effect on nonirradiated lesions (abscopal effect) in addition to the ablation of irradiated tumors. However, this effect occurs only in rare circumstances in clinical practice, and mechanisms underlying the abscopal effect of RT are neither fully understood nor therapeutically utilized. Here we identified that intercellular adhesion molecule-1 (ICAM-1), an inducible glycoprotein of the immunoglobulin superfamily, is up-regulated in nonirradiated tumors responsive to RT. ICAM-1 expression in preclinical animal models can be noninvasively detected by optical imaging and positron emission tomography (PET) using near-infrared fluorescence dye- and 64Cu-labeled imaging probes that we synthesized, respectively. Importantly, the expression levels of ICAM-1 determined by quantitative PET imaging showed a strong negative linear correlation with the growth of nonirradiated tumors. Moreover, genetic or pharmacologic up-regulation of ICAM-1 expression by either an intratumoral injection of engineered recombinant adenovirus or systemic administration of a Toll-like receptor 7 agonist-capsulated nanodrug could induce markedly increased abscopal responses to local RT in animal models. Mechanistic investigation revealed that ICAM-1 expression can enhance both the activation and tumor infiltration of CD8+ T cells to improve the responses of the nonirradiated tumors to RT. Together, our findings suggest that noninvasive PET imaging of ICAM-1 expression could be a powerful means to predict the responses of nonirradiated tumors to RT, which could facilitate the exploration of new combination RT strategies for effective ablation of primary and disseminated lesions. Significance Although RT serves as a frontline therapy for more than 50% of patients with malignancies, its efficacy is limited to localized tumors. Efforts in harnessing the abscopal effect of RT could systemically eliminate metastatic lesions disseminated beyond the radiation field; however, success has been limited thus far, owing to an inadequate understanding of the underlying mechanisms and an absence of reliable biomarkers for early prediction. Here we demonstrate that noninvasive PET imaging of ICAM-1 expression confers predictive value for abscopal effect efficacy at an early stage. This strategy may also facilitate potential high-throughput screening of current or novel drugs to be used in combination with RT to achieve desired antitumor therapeutic outcomes that eliminate both primary and metastatic lesions.
- 30 March 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (14)
ICAM-1 orchestrates the abscopal effect of tumor radiotherapy
Compelling evidence indicates that radiotherapy (RT) has a systemic inhibitory effect on nonirradiated lesions (abscopal effect) in addition to the ablation of irradiated tumors. However, this effect occurs only in rare circumstances in clinical practice, and mechanisms underlying the abscopal effect of RT are neither fully understood nor therapeutically utilized. Here we identified that intercellular adhesion molecule-1 (ICAM-1), an inducible glycoprotein of the immunoglobulin superfamily, is up-regulated in nonirradiated tumors responsive to RT. ICAM-1 expression in preclinical animal models can be noninvasively detected by optical imaging and positron emission tomography (PET) using near-infrared fluorescence dye- and 64Cu-labeled imaging probes that we synthesized, respectively. Importantly, the expression levels of ICAM-1 determined by quantitative PET imaging showed a strong negative linear correlation with the growth of nonirradiated tumors. Moreover, genetic or pharmacologic up-regulation of ICAM-1 expression by either an intratumoral injection of engineered recombinant adenovirus or systemic administration of a Toll-like receptor 7 agonist-capsulated nanodrug could induce markedly increased abscopal responses to local RT in animal models. Mechanistic investigation revealed that ICAM-1 expression can enhance both the activation and tumor infiltration of CD8+ T cells to improve the responses of the nonirradiated tumors to RT. Together, our findings suggest that noninvasive PET imaging of ICAM-1 expression could be a powerful means to predict the responses of nonirradiated tumors to RT, which could facilitate the exploration of new combination RT strategies for effective ablation of primary and disseminated lesions. Significance Although RT serves as a frontline therapy for more than 50% of patients with malignancies, its efficacy is limited to localized tumors. Efforts in harnessing the abscopal effect of RT could systemically eliminate metastatic lesions disseminated beyond the radiation field; however, success has been limited thus far, owing to an inadequate understanding of the underlying mechanisms and an absence of reliable biomarkers for early prediction. Here we demonstrate that noninvasive PET imaging of ICAM-1 expression confers predictive value for abscopal effect efficacy at an early stage. This strategy may also facilitate potential high-throughput screening of current or novel drugs to be used in combination with RT to achieve desired antitumor therapeutic outcomes that eliminate both primary and metastatic lesions.